These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2730023)

  • 1. [Tumor metastasis and the fibrinolytic system].
    Yamamura M; Yamamoto M
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1246-54. PubMed ID: 2730023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
    Ostrowski LE; Ahsan A; Suthar BP; Pagast P; Bain DL; Wong C; Patel A; Schultz RM
    Cancer Res; 1986 Aug; 46(8):4121-8. PubMed ID: 3089587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
    Palumbo JS; Potter JM; Kaplan LS; Talmage K; Jackson DG; Degen JL
    Cancer Res; 2002 Dec; 62(23):6966-72. PubMed ID: 12460914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
    Eisenbach L; Segal S; Feldman M
    J Natl Cancer Inst; 1985 Jan; 74(1):77-85. PubMed ID: 3855489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
    Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
    Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
    Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
    Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasminogen activator inhibitor "paradox" in cancer.
    Binder BR; Mihaly J
    Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
    Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE
    Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.
    Capo-Chichi CD; Smith ER; Yang DH; Roland IH; Vanderveer L; Cohen C; Hamilton TC; Godwin AK; Xu XX
    Cancer; 2002 Oct; 95(8):1802-15. PubMed ID: 12365030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation and fibrinolysis in cancer.
    Heimburger N; Pâques EP; Römisch J
    Behring Inst Mitt; 1992 Apr; (91):169-82. PubMed ID: 1388019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
    Tsuchiya H; Katsuo S; Matsuda E; Sunayama C; Tomita K; Ueda Y; Binder BR
    Gen Diagn Pathol; 1995 May; 141(1):41-8. PubMed ID: 8542506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines.
    Wang BS; McLoughlin GA; Richie JP; Mannick JA
    Cancer Res; 1980 Feb; 40(2):288-92. PubMed ID: 7356511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological consequences of loss of plasminogen activator gene function in mice.
    Carmeliet P; Schoonjans L; Kieckens L; Ream B; Degen J; Bronson R; De Vos R; van den Oord JJ; Collen D; Mulligan RC
    Nature; 1994 Mar; 368(6470):419-24. PubMed ID: 8133887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The location of components of fibrinolytic system in laryngeal cancer].
    Sierko E; Tokajuk P; Zimnoch L; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2003 Jul; 15(85):81-5. PubMed ID: 14593967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.